Entrectinib, with similar potency, inhibits anaplastic lymphoma kinase (ALK), ROS1 and tropomyosin receptor kinase (TRK), showing antiproliferative activity in cancers originating from gene fusion mutations involving these proteins. The gene discussed is NTRK1; the disease is cancer.